{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:17:13Z","timestamp":1789697833665,"version":"4.0.1"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T00:00:00Z","timestamp":1380067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>74, expressed in multiple myeloma (<jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>), was evaluated as a target for immunotherapy with milatuzumab (a humanized anti\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>74 antibody). In a multicentre dose escalation study, 25 patients with advanced <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> received milatuzumab doses of 1\u00b75 (<jats:italic>N\u00a0<\/jats:italic>=\u00a08), 4\u00b70 (<jats:italic>N\u00a0<\/jats:italic>=\u00a09), 8\u00b70 (<jats:italic>N\u00a0<\/jats:italic>=\u00a04) or 16\u00b70\u00a0mg\/kg (<jats:italic>N\u00a0<\/jats:italic>=\u00a04) administered twice weekly x 4. They had a median of 5 prior treatments (17 post \u22651 stem cell transplantation) and were refractory (<jats:italic>N\u00a0<\/jats:italic>=\u00a07) or relapsed (<jats:italic>N\u00a0<\/jats:italic>=\u00a018) with generally short\u2010lived responses to last treatment (median 4\u00b70\u00a0months). After increasing prophylactic medications and slowing administration, infusions were well tolerated (National Cancer Institute\u2010Common Terminology Criteria v3 toxicity Grades 1\u20132) with no dose\u2010limiting toxicity at higher doses. Only one patient developed borderline positive human anti\u2010milatuzumab antibody titres of uncertain clinical significance. Although milatuzumab was rapidly cleared from circulation with little serum accumulation and low trough levels, B\u2010cell levels were moderately decreased with treatment (median decrease, 34%). There were no objective responses by European Group for Blood and Marrow Transplantation criteria, but 5 of 19 patients (26%) who completed treatment in this heavily pretreated and generally refractory group had stable disease for \u22653\u00a0months post\u2010treatment (one continuing for 17\u00a0months). Disease stabilization and evidence of pharmacodynamic activity support further development for use in combination with other agents or as a drug conjugate. (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/Clinicaltrials.gov\">Clinicaltrials.gov<\/jats:ext-link> identifier: NCT00421525)<\/jats:p>","DOI":"10.1111\/bjh.12565","type":"journal-article","created":{"date-parts":[[2013,10,12]],"date-time":"2013-10-12T00:58:31Z","timestamp":1381539511000},"page":"478-486","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Phase I, multicentre, dose\u2010escalation trial of monotherapy with milatuzumab (humanized anti\u2010<scp>CD<\/scp>74 monoclonal antibody) in relapsed or refractory multiple myeloma"],"prefix":"10.1111","volume":"163","author":[{"given":"Jonathan L.","family":"Kaufman","sequence":"first","affiliation":[{"name":"Emory University School of Medicine Winship Cancer Institute Atlanta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College New York Presbyterian Hospital New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Stadtmauer","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center University of Pennsylvania Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher","family":"Chanan\u2010Khan","sequence":"additional","affiliation":[{"name":"Roswell Park Cancer Institute Buffalo NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Siegel","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center Hackensack NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Horne","sequence":"additional","affiliation":[{"name":"Immunomedics Inc Morris Plains NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Wegener","sequence":"additional","affiliation":[{"name":"Immunomedics Inc Morris Plains NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Goldenberg","sequence":"additional","affiliation":[{"name":"Immunomedics Inc Morris Plains NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,9,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-303354"},{"key":"e_1_2_9_3_1","first-page":"2809","volume-title":"Cancer Medicine","author":"Anderson K.C.","year":"1997"},{"key":"e_1_2_9_4_1","first-page":"1279","volume-title":"Williams Hematology","author":"Barlogie B.","year":"2001"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0701553104"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0904149"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0182"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.12.040194.001355"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"e_1_2_9_12_1","first-page":"243","volume-title":"Recent Advances in Hematology","author":"Durie B.G.M.","year":"1977"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200312"},{"key":"e_1_2_9_14_1","first-page":"1557","volume-title":"Neoplastic Hematopathology","author":"Grogan T.M.","year":"2001"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-381988"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-253203"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.2649"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2046"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.1999.00868.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5460"},{"key":"e_1_2_9_21_1","first-page":"4568","article-title":"Two new monoclonal antibodies, EPB\u20101 and EPB\u20102, reactive with human lymphoma","volume":"49","author":"Pawlak\u2010Bycskowska E.J.","year":"1989","journal-title":"Cancer Research"},{"key":"e_1_2_9_22_1","first-page":"73","article-title":"Daratuzumab, a CD38 monoclonal antibody in patients with multiple myeloma: data from a dose\u2010escalation phase I\/II study","volume":"120","author":"Plesner T.","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.0221"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08790.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0204"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20138"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4334"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0890"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1167"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1953"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/924058"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070596"},{"key":"e_1_2_9_35_1","first-page":"22","article-title":"Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives","volume":"1","author":"Yang J.","year":"2011","journal-title":"American Journal of Blood Research"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.51.5.273"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600564803"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-360552"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12565","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T23:41:43Z","timestamp":1696290103000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,25]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1111\/bjh.12565"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12565","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,25]]},"assertion":[{"value":"2013-06-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-08-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-09-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}